Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

Date: November 05, 2026

To

BSE Limited("BSE")	National Stock Exchange of India Ltd("NSE")
Phiroze Jeejeebhoy Towers	Exchange Plaza
2nd Floor, Dalal Street	Bandra-Kurla Complex,Bandra (E)
Mumbai- 400001	Mumbai- 4000051
BSE Scrip Code: 544866	Symbol: MOLBIO

Subject: Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), please find enclosed herewith a copy of the Investor Presentation or Communication, in connection with the Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026.

This presentation will also be available on the Company's website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same on record.

Thanking You.

Yours Faithfully,

For Molbio Diagnostics Limited

DARSHAN RAGHUNATH KAREKAR
Digitally signed by DARSHAN RAGHUNATH KAREKAR
Date: 2026.11.05 17:08:14 +05'30'

Darshan Raghunath Karekar
Company Secretary & Compliance Officer
M. No: F13569
Date: November 05,2026
Place: Verna-Goa

molbio®

INNOVATE • IMPACT • INSPIRE

Innovation Led Diagnostic Products Company



Investor Presentation
Nov'2026

Safe Harbour

*This presentation and the accompanying slides (the "Presentation"), which has been prepared by **Molbio Diagnostics Ltd.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company shall be made except by means of a statutory offering document containing detailed information about the Company.*

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Stakeholders are advised to compare the data provided in the presentation with the full financial results available on the website of the Company as well as on the website of the NSE and BSE.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Management Commentary

"H1 FY27 Total Income stood at ₹676.3 Cr, compared to ₹681.8 Cr in H1 FY26. During Q2 FY27, business performance was relatively softer as we were in the midst of rate-contract negotiations, which typically take around 1–1.5 months to complete. Consequently, the quarter does not reflect a full three months of sales.

As highlighted previously, our business is not linear, and performance may vary from quarter to quarter. Historically, H1 has contributed around 35–45% of our full-year revenue. We remain committed to working towards our guidance of 25% topline growth in FY27 over FY26.

Alongside our focus on business growth, we are making good progress in expanding our global presence and further strengthening our R&D portfolio. We are in advanced stages of developing new platforms to address the evolving requirements of laboratories, hospitals and doctors' clinics.

We are also pleased to share that our radiology products, in addition to their applications in human healthcare, are now being deployed for veterinary use. To further strengthen our presence in veterinary segment, we are in the process of developing six new assays for veterinary applications, which will be available on our Truenat® devices.

We remain focused on strengthening our technology and product portfolio, expanding our global footprint and pursuing our growth objectives. We believe these initiatives will further enhance our capabilities and support our long-term growth aspirations."



Sriram Natarajan


Executive Director, and Chief Executive Officer (CEO)

Company & Business Overview

Founders' Journey

1990-2004

2005-2018




Note: (1) Polymerase Chain Reaction
(2) Indian Council of Medical Research

Journey Post Commercial Launch of Truenat Platform

2019-2022

2023 onwards



2019

Investment by **Motilal Oswal Alternate Investment Advisors Pvt Ltd**[2]

2020

- **Launch of ICMR**[4] **approved COVID test**; BioSpectrum product of the year award
- **Truenat endorsement by WHO**[5] **for TB**[1]

2022

Investment by **Temasek Holdings (Private) Ltd**[3]

2023

Foray in **Radiology** via Prognosys Medical Systems Private Limited acquisition

2024

- Strategic investment in OptraSCAN, a **Digital Pathology Company**
- Launch of **EDGE incubator program**

2025

- **EU IVDR** Class C certification for Truenat® CT/NG
- Prognosys[5] received **US FDA 510(k)** clearance for Prorad Atlas Ultraportable and Prorad Atlas Ultraportable Plus

2026

- Prognosys[5] received **EU MDR certification** for the PRORAD radiology systems
- Truenat HR-HPV Plus met **IARC validation criteria** in a multicentre study
- Collaboration with **Equine Biotech** for veterinary diagnostics development
- **US FDA 510(k)** clearance for the OptraSCAN System
- Listed on **NSE & BSE**

Note: (1) For an initial diagnosis of TB (Tuberculosis) and rifampicin resistance detection using molecular diagnostic technology (Source: Report titled "Molecular Diagnostics Industry Report" dated August 22, 2025 ("1Lattice Report")) (5) World Health Organisation. (2) Investment through its funds. (3) Investment through its indirect wholly owned subsidiary. (4) Indian Council of Medical Research. (5) Prognosys Medical Systems Private Limited

Molbio At A Glance

Innovation-led diagnostics company delivering accessible, accurate and affordable molecular testing

Broad & Growing Test Menu

43
Assays

30
Diseases Covered

Across infectious diseases, women's health, oncology & more

Global Scale & Adoption

12,500+
Truenat® Devices Sold

90+
Countries with Truenat® Presence

17.6 Mn
Test Kits Sold in FY26

Recurring Business Model

73.98%
Product Revenue from Test Kits in FY26

₹ 1,455 Cr
Total Income in FY26

Proprietary Technology

Truenat®

Portable | Battery-operated Real-time PCR Platform

Rapid • Accurate • Easy to Use

Robust Innovation Engine

153
R&D Professionals (136 Scientists)

207
Registered Patents

Strong In-house R&D Capabilities Across Platform, Assays & Chemistry

WHO / ICMR / FIND Endorsed Platform for TB Diagnosis & Rifampicin Resistance

Multiple Regulatory Approvals & Clinical Validations

Financial Performance (FY26)

₹ 1,455 Cr	₹ 328 Cr	22.6%	₹ 164 Cr	11.3%
Total Income	EBITDA	EBITDA Margin	PAT	PAT Margin

Revenue & Customer Mix


Revenue By Product Line (₹ Crore)


Product Line	Q2 FY27	Q1 FY27	Q2 FY26	H1 FY27	H1 FY26
Truenat test kits	197	374	518	570	562
Truenat devices	31	15	51	46	69
Prognosys – radiology	9	11	6	20	11
OptraScan – digital pathology	5	1	0	6	0
Services / other	18	8	5	26	38
Total revenue from operations	259	408	580	667	680

Geographical Mix

Revenue by Geography	Q2 FY27	Q1 FY27	Q2 FY26	H1 FY27	H1 FY26
India	79%	83%	93%	81%	92%
Outside India	21%	17%	7%	19%	8%
Total	100%	100%	100%	100%	100%

Revenue Split





R&D Engine: Proven Innovation, Sustained Investment

Deep scientific capability translated into scalable products, protected IP and future growth

Proven Innovation Capability

From scientific insight to scalable impact

Multidisciplinary R&D spanning science, engineering, product development, evidence generation and scale-up.

13+ YEARS
R&D and translation behind Truenat®

153
R&D Professionals
Including 136 scientists


207
Patents
Granted in India and overseas

Built Across Disciplines
Biology • Chemistry • Software • Engineering
DSIR-recognised Bengaluru R&D facility

Innovation Beyond The Lab
Science → Product → Evidence → Scale → Impact

Investing More To Drive Future Growth

Annual R&D investment (₹ Cr)



₹87.5 Cr	46%	₹215.8 Cr
FY26 R&D spend	Increase vs FY24	Cumulative FY24–FY26

Idea → Product → Evidence → Scale → Impact → Future platforms, assays and revenue streams

Global Healthcare Burden - The Problem Statement

A significant diagnostic access gap continues to delay timely diagnosis, treatment and better health outcomes

Diagnostics Are Critical, Yet Underpenetrated

70% Healthcare decisions depend on diagnostic information

Only **3-5%** Healthcare budgets are allocated to diagnostic services

~3.6 Bn People (47% of the global population) have limited or no access to diagnostics

81% People in low-and lower-middle income countries lack access

- Diagnostic access is concentrated in urban and centralized laboratories
- Geographic distance, inadequate infrastructure and shortage of skilled professionals create major barriers
- Limited access leads to delayed diagnosis and sub-optimal outcomes

High Disease Burden Continues To Impact Global Health

10.7 Mn people fell ill with TB in 2024

1.23 Mn people died from TB in 2024

~2 in 5 people with drug-resistant TB accessed treatment

TB remains the world's leading cause of death from a single infectious agent.

Antimicrobial Resistance (Amr) - A Growing Concern

- Rising AMR increases the need for accurate pathogen identification and resistance detection
- Limited diagnostic capacity restricts appropriate treatment and drives inappropriate antibiotic use
- Stronger diagnostics is essential for AMR surveillance and stewardship

Infectious Diseases - A Persistent Burden

- Early detection and accurate diagnosis are critical for better patient outcomes
- Diagnostic gaps weaken disease surveillance and outbreak preparedness
- High burden in emerging and resource-limited settings

From Centralized To Decentralized Point Of Care Diagnostics

Emerging Need Decentralized / Point-of-care Diagnostics



Test at or near the patient



Minimal infrastructure



Faster Results



Earlier clinical decision



Greater reach & impact



Traditional Model Centralized Laboratory Diagnostics



Sample collected at patient site



Sample transported to central lab



Infrastructure dependent



Specialist workforce



Longer turnaround time (hours-days)

Bridging the diagnostic access gap with accurate, rapid and decentralised testing is essential to improve health outcomes, strengthen disease control and build more resilient healthcare systems.

The Truenat Platform - An Integrated Workflow

Device

UnoDx (1 test)

Duo (2 tests)

Quattro (4 tests)



Key Platform Attributes

Portable
Lightweight and easy to transport

Fully Automatic
Minimal hands-on time and easy to use

Battery Operated
Works in areas with unreliable power

Point-of-care Ready
Designed for use at or near the patient

RAPID RESULTS
Sample to result in ~60 minutes®

Multi-disease Platform

43 ASSAYS

30 DISEASES

- **Disease-specific micro-PCR chips** operate on the same core platform
- Menu spans infectious and non-communicable diseases
- Includes **TB, Hepatitis B/C, HIV, HPV, COVID-19** and many more
- Platform designed to accommodate additional assays

- **TB**
- **Hepatitis**
- **HIV**
- **HPV**
- **COVID - 19**
- **Dengue**
- **Influenza & more**

Consumables - Powering A Recurring Revenue Engine

Disease-specific Consumables

- Truenat® test kits are disease-specific, ready-to-use and single-use
- Micro-PCR chips contain pre-loaded PCR reagents for real-time PCR testing
- Designed for use exclusively with the Truenat® platform
- Expanding assay menu increases utility and potential utilization of the installed base

What Constitutes The Consumable

Truenat Test Kit



Cartridge-based Sample Preparation

+



Pre-loaded PCR Reagents


+



Truenat® Micro-PCR Chip


Strong Growth In Test-kit Consumption

Test Kits Sold (Units)



~41%
CAGR
in Test Kit Volumes FY24-FY26

Test Kits As % Of Product Revenue



Truenat Business Model, Installed Base & Unit Economics

Device placements establish the platform; proprietary test kits create recurring revenue.

Core Recurring - Revenue Engine

DEPLOY
Hospitals, labs, PHCs and public-health programmes install portable Truenat machines.

TEST
Samples processed on-platform; results in about 60 minutes.

CONSUME KITS
Each test uses a proprietary disposable kit, generating repeat revenue.

EXPAND USAGE
Higher utilisation, more assays and new geographies can lift kit sales.

INSTALLED BASE & FY26 REALISATIONS

12,500+
Sold Globally

~8,000 - 10,000
India installed base

~₹589
FY26 kit Realisation
Blended Average

~₹8,05,404
FY26 Device Realisation
Blended Average

Operating Dashboard

KPI	Q2 FY27	Q1 FY27	Q2 FY26	H1 FY27	H1 FY26
Devices sold (units)	395	164	647	559	860
Test kits sold (Mn units)	3.24	6.24	8.73	9.47	9.52
Avg kit realisation (₹)	607	599	593	602	591
Avg device realisation (₹ lakh)	7.88	8.89	7.82	8.18	8.03


Molbio has Presence across 30 Diseases in the Fast-Growing POCT Market for Infectious Diseases

Infectious Disease Testing Represents Significant Segment of Global POC(4) Market...


...With TB Tests Being the Leading Contributor

Significant Testing Market Across Diseases


Global POC(4) Diagnostic Market Split by Therapy Area ($b, CY25)



Global POC(4) Market Size for Infectious Diseases ($b, CY25)



POC(4) Tests Conducted (Million Tests, CY25)



✓ *Indicates Molbio has existing commercialised tests*

Point-of-Care Diagnostics Global TAM(2) of ~$29.3b in CY25 Growing to ~$67.1b in CY30 at 17.9% CAGR(1)

Note: All industry data is sourced from report titled "Molecular Diagnostics Industry Report" dated July 24, 2026 ("1Lattice Report") unless otherwise specified
(1) 2025-30P CAGR
(2) Total Addressable Market
(3) Point of care testing
(4) Point of care
(5) Gastrointestinal
(6) Sexually transmitted infection
(7) Human Papillomavirus
(8) Hepatitis C virus
(9) Hepatitis B
(10) Tuberculosis

State of Art Manufacturing Facilities

Scaled, Multi-location Manufacturing Footprint

6 Manufacturing Facilities | 4 Locations

GOA **2 FACILITIES**	Manufacturing of Truenat® Test Kits
VISAKHAPATNAM **1 FACILITY**	Manufacturing of Truenat® Devices & Test Kit Components
BENGALURU **2 FACILITIES**	Manufacturing of Test Kit Components & Radiology Devices
PUNE **1 FACILITY**	Manufacturing of Digital Pathology Scanners

Geographically diversified facilities across key product categories ensure continuity, redundancy and scalability


Meaningful Installed Capacity With Headroom

TRUENAT® TEST KITS

39 Mn

KITS / ANNUM

FY26 UTILISATION




TRUENAT® DEVICES

5,400

DEVICES / ANNUM

FY26 UTILISATION



Early investments in capacity provide headroom to support future growth in test kits and devices

Automation-enabled Manufacturing

Automation For Precision & Consistency

- Leveraging automation and advanced processes to improve precision, consistency and process efficiency

Integrated & Flexible Operations

- In-house manufacturing of core products
- EMS partners leveraged for Truenat® device assembly to meet demand efficiently

Scale With Quality

- Strong process control, validation and monitoring ensures consistent quality at scale

A flexible manufacturing architecture that combines in-house capabilities with outsourced assembly scalability

Quality Certifications

Integrated Quality Assurance & Quality Control

221 QA / QC PROFESSIONALS

- Dedicated QA-QC division at each manufacturing facility
- Rigorous testing of raw materials, in-process and finished products
- 100% quality control checks of test kits, reagents and cartridges before dispatch
- Quality systems spanning design, development, manufacturing, distribution and servicing

Design & Development

Manufacturing

Quality Control

Distribution

Servicing

International Quality Management Systems

ISO 13485:2016

ISO

Certified Quality Management System for Design, Development, Manufacturing, Distribution and servicing of:

- IVD reagents and kits
- Near-patient / POC IVD medical devices

MDSAP

MDSAP

Quality Management System assessed against requirements of multiple regulatory jurisdictions:


BRAZIL

CANADA

USA

Certified by TÜV SÜD Product Service GmbH

Regulatory & Product-level Validation



EU IVDR CLASS C

First Indian company to receive EU IVDR Class C Technical Documentation Assessment Certificate for Truenat® CT/NG

icmr Recognised | World Health Organization Endorsed | FIND Diagnostic Solutions | EU IVDR Compliant | MDSAP Certified | ISO 13485:2016 Certified

Prognosys: Step Towards Enhancing Our Universal Access Portfolio with Radiology Imaging Devices

Prognosys Medical Systems (2)
a molbio company

Prognosys Acquisition Unlocking Multiple Levers to Enhance Our Digital Radiology Capabilities







US FDA approved range of **digital imaging solutions** with a strong pipeline of **ultra portable devices** across various X-Ray Systems

End-to-End TB(1) Testing

PRORAD
X-Ray screening for TB(1)

Truenat®
RT-PCR(3) confirmatory test for TB(1)

Note: All industry data is sourced from report titled "Molecular Diagnostics Industry Report" dated July 24, 2026 ("1Lattice Report") unless otherwise specified
(1) Tuberculosis
(2) Acquisitions
(3) Reverse transcription- Polymerase chain reaction

AI-powered, Digital Pathology Solutions Enabling Remote Consultations and Collaborations

OptraSCAN® On-Demand Digital Pathology

Investment in US based Company Furthering Global Reach and Diversifying Offerings

Whole Slide Scanner



OS-SiX™ Brightfield Scanner (6 slides)



OS-Lite™ Brightfield Scanner (15 slides)



OS-Ultra™ Brightfield Scanner (80-480 slides)



OS-FiA Cytology Scanner



OS-FS™ Frozen Sections Scanner



OS-FLi™ Fluorescence and Brightfield

Comprehensive Digital pathology Solutions

Provides digital pathology solutions, offering a range of digital pathology scanners, AI-powered analysis tools, and telepathology services, enabling remote consultations and collaboration

Wide Product Portfolio

Key products include OS 15 Scanner (scans 15 slides), OS Ultra Series (80, 160, 240, 320, 400 & 480) which scans in under 60 seconds without compromising image quality, and OS Lite, which is wirelessly-enabled for flexible storage, archiving, and management of digital images and metadata

Regulatory Milestones

Received US FDA 510(k) clearance (K260755) for its OptraScan System

Growth Strategy

Expand Our Geographical Presence across the Globe

Focus on enhancing exports, particularly to regions where we have presence, such as

- Africa
- Southeast Asia

Planning to enter markets with portfolio of Molbio products such as

- EU
- US

Develop New POC(1) Platforms for Other Communicable and Non-Communicable Diseases

Leverage R&D Capabilities to Develop New POC(1) Platforms Using Advanced Multiplex PCR(2) Technologies to Address Diagnostic Needs in:

- Immunochemistry
- Hematology
- Histopathology
- Biochemistry
- Antimicrobial Resistance

Communicable Diseases

Non-Communicable Diseases

Expand Our Suite of Tests for Truenat®

HUMAN	VETERINARY
34 Assays in Pipeline	Rabies Assay
22 Diseases in Pipeline	**06** Assays in Pipeline

Grow Inorganically Through Strategic Acquisitions and Alliances

Expertise in Strategic Acquisitions to Help Expand Capabilities...

- Prognosys Medical Systems, a molbio company
- OptraSCAN® On-Demand Digital Pathology

...And Collaborations to Enhance Portfolio Offerings

- HealSeq
- XCyton
- UE LifeSciences
- Stellar
- TESTi TECHNOLOGIES

Accelerating Innovation via EDGE Program

Establishing Centre of Excellence (CoE) at Bengaluru

R&D Pipeline

Trueamp®



Designed for custom panel testing, the Trueamp™ Mini is a portable analyzer, analysing up to 16 targets per run

Truepoc™



A fully integrated, one-step, near point-of-care molecular diagnostics platform that detects TB in both sputum swabs and tongue swabs

Truecyte®




AI-powered digital pathology system that delivers rapid, PBS-based diagnostics at the point of care. For application in human and veterinary use.

Financials Performance - Quarter


Q2 FY27 Performance Highlight (Y-O-Y)

Total Income*	EBITDA*	EBITDA Margin	PAT	PAT Margin
₹265 Cr	₹50 Cr	18.8%	₹8 Cr	2.9%

Truenat® Devices Sold (Units)



Truenat® Test Kits Sold (Mn Units)




Total Income & EBITDA includes other income


H1 FY27 Performance Highlight (Y-O-Y)

Total Income*	EBITDA*	EBITDA Margin	PAT	PAT Margin
₹676 Cr	₹153 Cr	22.7%	₹60 Cr	8.9%

Truenat® Devices Sold (Units)




Truenat® Test Kits Sold (Mn Units)




Total Income & EBITDA includes other income

Profit & Loss Highlights – Quarterly


Total Income* (₹ Cr.)



EBITDA* (₹ Cr) & Margin %



Net Profit (₹ Cr) & Margin %



**Total Income & EBITDA includes other income*

Profit & Loss Statement – Quarterly

Particulars (₹ Cr)	Q2 FY27	Q2 FY26	Q1 FY27
Revenue from Operations	259.0	580.3	408.4
Other income	5.8	1.1	3.1
Total income	**264.8**	**581.4**	**411.5**
COGS	99.4	222.5	149.7
Employee Benefit Expenses	37.8	33.9	45.9
Other Expenses	77.9	155.7	112.2
EBITDA	**49.7**	**168.5**	**103.7**
EBITDA Margin %	**18.8%**	**29.0%**	**25.2%**
Finance Costs	8.9	7.0	10.7
Depreciation	23.4	13.8	17.1
PBT	**17.5**	**148.5**	**75.9**
Exceptional items (net)	0.0	0.0	0.0
Share of loss of associates	0.0	(0.8)	0.0
Tax Expenses	9.8	40.9	23.2
PAT	**7.7**	**106.8**	**52.7**
PAT Margin %	**2.9%**	**18.4%**	**12.8%**
Basic EPS (₹)	**1.3**	**9.7**	**5.2**

Profit & Loss Statement – Half Yearly

Particulars (₹ Cr)	H1 FY27	H1 FY26
Revenue from Operations	667.4	680.0
Other income	8.9	1.9
Total income	**676.3**	**681.8**
COGS	249.1	257.6
Employee Benefit Expenses	83.7	62.1
Other Expenses	190.1	207.4
EBITDA	**153.4**	**153.2**
EBITDA Margin %	**22.7%**	**22.5%**
Finance Costs	19.6	10.6
Depreciation	40.4	26.1
PBT	**93.4**	**118.1**
Exceptional items (net)	0.0	0.0
Share of loss of associates	0.0	(1.6)
Tax Expenses	33.0	33.6
PAT	**60.4**	**82.9**
PAT Margin %	**8.9%**	**12.2%**
Basic EPS (₹)	**6.5**	**7.6**

Financial Statement (₹ Cr) – Consolidated

Balance Sheet	H1FY27	FY26
Equity Share Capital	11.5	11.3
Other Equity	1,428.9	1,158.1
Non-controlling interest	126.8	139.4
Total Equity	**1,567.3**	**1,308.8**
Non-Current Liabilities		
Borrowings	193.9	212.4
Lease Liabilities	27.9	27.2
Others	40.1	42.7
Current Liabilities		
Borrowings	157.7	200.2
Lease Liabilities	10.3	10.2
Trade Payables	149.5	199.5
Others	182.1	147.4
Total Equity & Liabilities	**2,328.7**	**2,148.4**

Balance Sheet	H1FY27	FY26
Non-Current Assets		
Property, Plant and Equipment	243.3	248.1
Right of Use Asset	55.0	55.4
Goodwill	62.1	62.1
Other Intangible Assets	159.8	170.8
Intangible Assets Under Development	-	-
Others	219.4	227.2
Current Assets		
Inventories	456.3	449.3
Trade Receivables	302.3	408.7
Cash and Cash Equivalents	493.1	355.5
Others	337.4	171.3
Total Assets	**2,328.7**	**2,148.4**

Cash Flows Statement	H1FY27	H1FY26
Cash Flow Generated from/(Used in) Operating Activities	167.1	(239.3)
Cash Flow from/(Used in) Investing Activities	(141.0)	(15.4)
Cash Flow from/(Used in) Financing Activities	89.6	60.6
Net Increase/(Decrease) in Cash and Cash Equivalents	**115.8**	**(194.0)**
Opening Cash and Cash Equivalents	338.8	63.2
Closing Cash and Cash Equivalents	**454.6**	**(130.8)**

Value Proposition

Proprietary POC Molecular Diagnostics Platform

- Truenat® brings real-time PCR capabilities closer to the patient
- Portable, battery-operated platform designed for decentralised testing
- Enables molecular diagnostics in resource constrained and remote settings

Speed & Accessibility

- Delivers molecular test results in **~60 minutes** for relevant Truenat® workflows
- Reduces dependence on centralised laboratories and sample transportation
- Enables faster diagnosis and treatment initiation at the point of care

Accuracy With Clinical & Regulatory Validation

- Real-time PCR-based technology designed to deliver laboratory-comparable diagnostic performance
- Validated across multiple disease applications
- WHO / ICMR and other regulatory & clinical validations strengthen credibility

One Platform | Multiple Diseases

- 43 assays covering 30 diseases as of March 2026
- Expanding menu across infectious diseases, women's health, oncology and other applications
- Growing assay portfolio increases the utility and potential utilisation of the installed base

Scalable & Recurring Business Model

- 12,500+ Truenat® devices sold across 90+ countries
- Installed instruments create an opportunity for repeat test-kit consumption
- Test kits contributed ~74% of product revenue in FY26, demonstrating the growing consumables-led revenue mix

Innovation-led Growth Engine

- Strong in-house R&D capabilities supported by 153 R&D professionals
- 207 registered patents underpin the technology and innovation ecosystem
- Continuous investment in new assays, applications and next-generation POC platforms expands the addressable opportunity

THANK YOU



For any investor queries, please contact

Molbio Diagnostics Limited
Indraneil Borkakoty - President – Corporate Strategy, Mergers & Acquisitions and Investor Relations
indraneil.borkakoty@molbiodiagnostics.com

Adfactors PR - Investor Relations
Smit Shah / Anand Venugopal
+91 98707 89596 / +91 70218 52071
smit.shah@adfactorspr.com / anand.venugopal@adfactorspr.com